Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lexicon Pharmaceuticals reports strong Q4 performance and eyes growth

Lexicon Pharmaceuticals showcased promising drug candidates and financial stability in Q4 2022.
While facing challenges in revenue generation and expense management, the company is strategically positioned for growth.
Opportunities lie in commercial launches, Phase 3 advancements, and potential partnerships to drive future success.
Overall, Lexicon's focus on maximizing asset value and advancing key drugs positions them for long-term success in the pharmaceutical market.

Lexicon Pharmaceuticals reports robust Q1 performance and eyes market expansion

Lexicon Pharmaceuticals showcased strong financials, promising drug candidates, and strategic confidence in market success.
Challenges lie in market penetration strategies, FDA feedback, and successful commercialization amidst competition.
Opportunities abound with upcoming sotagliflozin launch, advancing LX9211, and leveraging unique data for growth.

Lexicon Pharmaceuticals reports strong Q2 earnings and advances key treatments

Lexicon Pharmaceuticals demonstrated financial stability and strategic progress in Q2 2023, supported by strong cash reserves and key regulatory milestones.
The company's focus on patient-centric initiatives and upcoming product launches positions it for sustained growth and market success.
Challenges in market penetration and revenue realization require targeted strategies, while opportunities in market expansion and pipeline development offer avenues for growth.
Overall, Lexicon Pharmaceuticals shows promise with a solid foundation for future success, driven by innovation and market-focused strategies.

Lexicon Pharmaceuticals reports Q3 loss, highlights INPEFA progress and global expansion

Lexicon Pharmaceuticals faces challenges in market access and inventory trends while capitalizing on opportunities through geographic expansion and potential partnerships. The company's financial performance in Q3 2023 showed increased expenses but progress in prescription demand for INPEFA.

Lexicon Pharmaceuticals reports strong Q1 performance and growth opportunities

Lexicon Pharmaceuticals showcased strong performance and progress in Q1 2024, with a focus on product launches and market access.
Despite challenges in achieving full access and addressing specific patient needs, the company remains optimistic about future growth opportunities.
Positive customer feedback, ongoing pipeline advancements, and strategic market considerations position Lexicon well for future success and sales acceleration.

Lexicon Pharmaceuticals reports Q3 progress amidst financial challenges and opportunities

Lexicon Pharmaceuticals showcased progress in key development programs and strategic partnerships in Q3 2024.
Despite financial challenges, the company's operational strengths and focus on growth opportunities are notable.
Navigating uncertainties around ZYNQUISTA and competition in the market are key challenges ahead.
Overall, the company's performance, strengths, challenges, and opportunities shape its strategic outlook for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

THE WOODLANDS, Texas, Sept.  04, 2020  (GLOBE NEWSWIRE) --  Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX), announced today the commencement of patient dosing with blinded study drug in RELIEF-DPN-1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of LX9211 for the treatment of diabetic peripheral neuropathic pain. LX9211 is a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1).

Lexicon Pharmaceuticals Announces Commencement of Patient Dosing in RELIEF-DPN-1 Phase 2 Clinical Study of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain

THE WOODLANDS, Texas, Sept.  03, 2020  (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following conferences:

Lexicon Pharmaceuticals to Participate in the Citi 15ᵗʰ Annual BioPharma Virtual Conference and the Wells Fargo 2020 Virtual Healthcare Conference

Dynavax Technologies

iShares Nasdaq Biotechnology ETF

ImmunoGen

Viking Therapeutics

Xencor

The second half of 2020 is well underway, and with markets recovering, one of the strongest industries leading the charge has been biotech.

5 Speculative Biotechs With 50% to 300% Implied Upside

Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q2 2020 Results - Earnings Call Transcript

Phase 2 Study for Diabetic Peripheral Neuropathic Pain Underway, Additional Studies Planned in Other Areas of Neuropathic Pain

Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program

Lexicon to Receive Up to $224 Million in Upfront and Milestone Payments Plus Mid-Teens Royalties on Net Sales of XERMELO in Biliary Tract Cancer Lexicon to Receive Up to $224 Million in Upfront and Milestone Payments Plus Mid-Teens Royalties on Net Sales of XERMELO in Biliary Tract Cancer

Lexicon Pharmaceuticals Enters Into Agreement With TerSera Therapeutics for the Sale of XERMELO

Biogen

Coherus BioSciences

Gen Digital Inc

Salarius Pharmaceuticals Inc

A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects.

5 Value Stocks In The Healthcare Sector

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Lexicon Pharmaceuticals (LXRX) Q2 Earnings Expected to Decline

Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) shares surged on Tuesday after the company announced positive topline data for its late-stage studies in type 2 diabetes.

Late-Stage Diabetes Study Sets the Stage for Lexicon Pharma

THE WOODLANDS, Texas, July  21, 2020  (GLOBE NEWSWIRE) --  Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX), today announced topline data from four Phase 3 sotagliflozin studies in type 2 diabetes: SOTA-MONO, SOTA-SU, SOTA-GLIM and SOTA-INS. The final results of these studies will be preserved for upcoming medical congresses and publications.

Lexicon Pharmaceuticals Announces Topline Phase 3 Data From Four Phase 3 Sotagliflozin Studies in Type 2 Diabetes

THE WOODLANDS, Texas, July  20, 2020  (GLOBE NEWSWIRE) --  Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX), announced today that four posters highlighting XERMELO ®  (telotristat ethyl) will be presented at the virtual Cholangiocarcinoma Foundation Annual Conference (July 22-24).

Lexicon Pharmaceuticals Announces Poster Presentations at the Virtual Cholangiocarcinoma Foundation Annual Conference

THE WOODLANDS, Texas, June  13, 2020  (GLOBE NEWSWIRE) --   Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX), today presented six posters for ZynquistaTM (sotagliflozin) at the virtual 80th American Diabetes Association (ADA) Scientific Sessions including additional efficacy and safety data patients with type 2 diabetes and moderate and severe renal impairment.

Lexicon Pharmaceuticals Presents Clinical Data at 80th American Diabetes Association Scientific Sessions

THE WOODLANDS, Texas, May  27, 2020  (GLOBE NEWSWIRE) --  Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX)  today announced that Lonnel Coats, President and Chief Executive Officer, will present at the following conference:

Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

THE WOODLANDS, Texas, May  13, 2020  (GLOBE NEWSWIRE) --  Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX), announced today additional data on XERMELO’s ®  (telotristat ethyl) antiproliferative effects against cultured liposarcoma, colon cancer and cholangiocarcinoma cell lines that were published online in conjunction with the American Society of Clinical Oncology (ASCO) 2020 annual meeting (May 29 - June 2, 2020). XERMELO is approved for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy, but is not currently approved for any other use.

Lexicon Pharmaceuticals Announces Preclinical Efficacy Data on Telotristat Ethyl’s Antiproliferative Effects Against Various Cancer Cell Lines

The biotech company reported better-than-expected first-quarter results and now sees lower costs in 2020.

Why Lexicon Pharmaceuticals Stock Soared Today

Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q1 2020 Results - Earnings Call Transcript

Lexicon (LXRX) delivered earnings and revenue surprises of 4.55% and 11.47%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Tops Revenue Estimates

Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) were flat in pre-market trading after the company reported Q1 results.

Lexicon Pharmaceuticals: Q1 Earnings Insights

THE WOODLANDS, Texas, April  07, 2020  (GLOBE NEWSWIRE) --  Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) will host its 2020 annual meeting of stockholders in a virtual format only due to the public health impact of the coronavirus pandemic and to prioritize the health and well-being of meeting participants.

LEXICON PHARMACEUTICALS TO HOST VIRTUAL ANNUAL MEETING OF STOCKHOLDERS ON APRIL 23, 2020

Long-Term Outcomes Studies, SCORED and SOLOIST, to Close Out Early Long-Term Outcomes Studies, SCORED and SOLOIST, to Close Out Early

LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM

THE WOODLANDS, Texas, March  13, 2020  (GLOBE NEWSWIRE) --  Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX), announced today additional data on XERMELO’s ®  (telotristat ethyl) antiproliferative effects in patients with carcinoid syndrome that were presented at the European Neuroendocrine Tumor Society (ENETS) meeting (March 11-13). XERMELO is approved for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy, but is not currently approved for any other use.

LEXICON PHARMACEUTICALS ANNOUNCES ADDITIONAL DATA ON TELOTRISTAT ETHYL’S ANTIPROLIFERATIVE EFFECTS IN PATIENTS WITH CARCINOID SYNDROME

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported Q4 results. Quarterly Results • Earnings per share came in at a loss of $0.48, which beat the estimate calling for a loss of $0.77.

Lexicon Pharmaceuticals: Q4 Earnings Insights

Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q4 2019 Results - Earnings Call Transcript

Lexicon (LXRX) delivered earnings and revenue surprises of 36.84% and -17.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Misses Revenue Estimates

THE WOODLANDS, Texas, Jan.  24, 2020  (GLOBE NEWSWIRE) --  Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX), announced today real-world data on XERMELO’s ®  (telotristat ethyl) antiproliferative effects in patients with carcinoid syndrome that were presented at the American Society for Clinical Oncology (ASCO) 2020 Symposium (January 23-25, San Francisco, CA). XERMELO is approved for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy, but is not currently approved for any other use.

News for Lexicon Pharmaceuticals Stock (LXRX)